BTIG Research Reiterates “Buy” Rating for Verastem (NASDAQ:VSTM)

Verastem (NASDAQ:VSTM)‘s stock had its “buy” rating restated by BTIG Research in a report released on Tuesday, Benzinga reports. They currently have a $27.00 price objective on the biopharmaceutical company’s stock. BTIG Research’s target price would indicate a potential upside of 318.60% from the company’s previous close.

A number of other analysts also recently issued reports on VSTM. B. Riley began coverage on shares of Verastem in a report on Wednesday, September 27th. They set a “buy” rating and a $21.00 price objective for the company. Mizuho reiterated a “buy” rating and set a $36.00 price target on shares of Verastem in a report on Tuesday, August 29th. StockNews.com lowered shares of Verastem from a “hold” rating to a “sell” rating in a report on Monday, November 13th. Truist Financial lowered their price objective on shares of Verastem from $39.00 to $34.00 and set a “buy” rating for the company in a research note on Wednesday, November 15th. Finally, Royal Bank of Canada decreased their target price on Verastem from $34.00 to $32.00 and set an “outperform” rating for the company in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Verastem currently has a consensus rating of “Moderate Buy” and an average price target of $29.71.

Verastem Trading Up 1.9 %

NASDAQ:VSTM opened at $6.45 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.33 and a quick ratio of 7.33. Verastem has a 1 year low of $3.87 and a 1 year high of $15.18. The company has a market cap of $162.99 million, a P/E ratio of -1.60 and a beta of 0.56. The stock’s fifty day moving average price is $7.67 and its two-hundred day moving average price is $8.54.

Institutional Trading of Verastem

Several institutional investors and hedge funds have recently modified their holdings of VSTM. Maven Securities LTD purchased a new position in shares of Verastem in the second quarter worth $896,000. AlphaCentric Advisors LLC purchased a new stake in shares of Verastem during the 2nd quarter worth approximately $1,116,000. Arete Wealth Advisors LLC bought a new position in shares of Verastem during the 1st quarter valued at approximately $9,487,000,000. Virtu Financial LLC grew its holdings in shares of Verastem by 212.0% in the second quarter. Virtu Financial LLC now owns 41,048 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 27,890 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in Verastem during the first quarter valued at $37,000. 75.25% of the stock is currently owned by institutional investors.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK.